Description: The peptide sequence EAAGIGILTV is a decamer derived from the Melan-A/MART-1 protein, a melanocyte differentiation antigen predominantly expressed in melanoma cells. This peptide is presented by the HLA-A*0201 molecule and is recognized by cytotoxic CD8⁺ T lymphocytes (CTLs), making it a significant target in melanoma immunotherapy. Biological Role and Immunological Significance Antigenic Origin: EAAGIGILTV corresponds to amino acids 26–35 of the Melan-A/MART-1 protein. HLA Restriction: It is presented by the HLA-A*0201 allele, facilitating recognition by specific CTLs. T-Cell Activation: This epitope can stimulate antigen-specific CD8⁺ T-cell responses, which are crucial for targeting melanoma cells. Applications in Research and Clinical Settings: Immunomonitoring: EAAGIGILTV is utilized in assays like ELISPOT, intracellular cytokine staining, and tetramer staining to assess T-cell responses in patients and research subjects. Vaccine Development: Due to its specificity, this peptide serves as a candidate for peptide-based vaccines aiming to elicit robust anti-melanoma T-cell responses. Adoptive T-Cell Therapy: T cells specific to EAAGIGILTV can be expanded ex vivo and reinfused into patients to target melanoma cells. Considerations and Limitations: Immunogenicity: While EAAGIGILTV is naturally processed and presented, its immunogenicity is relatively low. To enhance T-cell responses, analogs like ELAGIGILTV have been developed, which exhibit improved binding to HLA-A*0201 and increased immunogenicity. TCR Specificity: T-cell receptors (TCRs) may distinguish between the natural peptide and its analogs, affecting the efficacy of T-cell responses. Structural studies have shown differences in TCR binding affinities between EAAGIGILTV and modified peptides. EAAGIGILTV is a pivotal epitope in melanoma immunotherapy research, serving as a target for T-cell-based interventions. Its role in activating CD8⁺ T cells makes it valuable for vaccine development, immunomonitoring, and adoptive cell therapies. However, considerations regarding its natural immunogenicity and TCR recognition are essential for optimizing therapeutic strategies. | The peptide sequence EAAGIGILTV is a decamer derived from the Melan-A/MART-1 protein, a melanocyte differentiation antigen predominantly expressed in melanoma cells. This peptide is presented by the HLA-A*0201 molecule and is recognized by cytotoxic CD8⁺ T lymphocytes (CTLs), making it a significant target in melanoma immunotherapy. Biological Role and Immunological Significance Antigenic Origin: EAAGIGILTV corresponds to amino acids 26–35 of the Melan-A/MART-1 protein. HLA Restriction: It is presented by the HLA-A*0201 allele, facilitating recognition by specific CTLs. T-Cell Activation: This epitope can stimulate antigen-specific CD8⁺ T-cell responses, which are crucial for targeting melanoma cells. Applications in Research and Clinical Settings: Immunomonitoring: EAAGIGILTV is utilized in assays like ELISPOT, intracellular cytokine staining, and tetramer staining to assess T-cell responses in patients and research subjects. Vaccine Development: Due to its specificity, this peptide serves as a candidate for peptide-based vaccines aiming to elicit robust anti-melanoma T-cell responses. Adoptive T-Cell Therapy: T cells specific to EAAGIGILTV can be expanded ex vivo and reinfused into patients to target melanoma cells. Considerations and Limitations: Immunogenicity: While EAAGIGILTV is naturally processed and presented, its immunogenicity is relatively low. To enhance T-cell responses, analogs like ELAGIGILTV have been developed, which exhibit improved binding to HLA-A*0201 and increased immunogenicity. TCR Specificity: T-cell receptors (TCRs) may distinguish between the natural peptide and its analogs, affecting the efficacy of T-cell responses. Structural studies have shown differences in TCR binding affinities between EAAGIGILTV and modified peptides. EAAGIGILTV is a pivotal epitope in melanoma immunotherapy research, serving as a target for T-cell-based interventions. Its role in activating CD8⁺ T cells makes it valuable for vaccine development, immunomonitoring, and adoptive cell therapies. However, considerations regarding its natural immunogenicity and TCR recognition are essential for optimizing therapeutic strategies. |
